Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 6, 1999, Pages 819-822

  Andrews, J M ^a   Ashby, J P ^a   Jevons, G M ^a   Wise, R ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; ENTEROBACTERIACEAE; ENTEROCOCCUS; HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA; MORAXELLA CATARRHALIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0032804074     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.6.819     Document Type: Article

References (7)

1. Dalhoff, A., Petersen, U. & Endermann, R. (1996). In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42, 410-25.
2. A Guide to Sensitivity Testing. (1991). Journal of Antimicrobial Chemotherapy 27, Suppl. D, 1-50.
3. Wise, R., Andrews, J. M. & Hartman, G. (1998). The pharmacokinetics and penetration of moxifloxacin into a cantharidine induced inflammatory exudate following oral and intravenous administration. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998, Abstract A27, p. 8. American Society for Microbiology, Washington, DC.
4. Grimm, H. (1999). Moxifloxacin: tentative interpretative criteria for the disc susceptibility testing using the German DIN 58940 method. In Abstracts of the Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 1999. Abstract P220, p. 143. Clinical Microbiology and Infection 5, Suppl. 3.
5. Grimm, H. (1999). Moxifloxacin: tentative interpretative criteria for the disc susceptibility testing using the German DIN 58940 method. In Abstracts of the Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 1999. Abstract P220, p. 143. Clinical Microbiology and Infection 5, Suppl. 3.
6. Krasemann, C., Meyer, J. M. & Springsklee, M. (1999). Suggested breakpoints for moxifloxacin. In Abstracts of the Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 1999. Abstract P206, p. 139. Clinical Microbiology and Infection 5, Suppl. 3.
7. Krasemann, C., Meyer, J. M. & Springsklee, M. (1999). Suggested breakpoints for moxifloxacin. In Abstracts of the Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 1999. Abstract P206, p. 139. Clinical Microbiology and Infection 5, Suppl. 3.